Contributions
Abstract: PS1208
Type: Poster Pitch
Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00
Location: Poster area
Background
Immunotherapy with CD19 CAR T cells achieves complete or partial remission in a fraction of patients with B cell malignancies, but disease progression remains common. IL-15 promotes T cell proliferation and survival and may enhance CAR T cell efficacy. However, exploiting native IL-15 is challenging due to its unfavorable pharmacokinetics and tolerability. In contrast, NKTR-255 is a polymer-conjugated IL-15 that retains binding affinity to IL15Rα and exhibits reduced clearance, providing sustained pharmacodynamic responses.
Aims
We investigated the effects of NKTR-255 on human CD19 CAR T cells both in vitro and in an in vivo xenogeneic B cell lymphoma model.
Methods
T cells expressing a CD19/4-1BB/CD3ζ CAR were generated from healthy donors. For in vitro studies, CAR T cells were incubated with NKTR-255 (0-100 ng/mL) with and without CD19 antigen. STAT5 phosphorylation and CFSE dilution were assessed by flow cytometry. For in vivo studies, NSG mice received 5x105 Raji lymphoma cells IV on day (D)-7 and a subtherapeutic dose (0.8x106) of CAR T cells (1:1 CD4:CD8) on D0. NKTR-255 (0.03-0.3mg/kg IV) was administered weekly starting on D-1, 7, or 14. Tumor-free mice were rechallenged with Raji cells. Tumors were assessed by bioluminescence imaging.
Results
In vitro, NKTR-255 led to dose-dependent STAT5 phosphorylation and increased antigen-dependent proliferation of CD8 CAR T cells. In vivo, infusion of NKTR-255 starting at D-1, 7 or 14 increased peak CAR T cell numbers in blood. Raji cells were eliminated from marrow by D14 in mice receiving CAR T cells and NKTR-255 on D7, but not CAR T cells alone. There was superior NKTR-255 dose-dependent tumor control and survival in mice receiving CAR T cells with NKTR-255 compared to CAR T cells or NKTR-255 alone. The benefit of combination therapy with NKTR-255 and CART T cells was greater when NKTR-255 was started by D7. Residual CAR T cells in NKTR-255-treated mice rejected re-challenge of Raji tumor cells administered beyond 5 weeks after CAR T cell infusion.
Conclusion
NKTR-255 administration improves the antitumor efficacy and kinetics of CD19 CAR T cells, supporting advancement into clinical trials of combination therapy with NKTR-255 and approved CD19 CAR T cell products.
Session topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Res
Keyword(s): Immunotherapy, Lymphoma
Abstract: PS1208
Type: Poster Pitch
Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00
Location: Poster area
Background
Immunotherapy with CD19 CAR T cells achieves complete or partial remission in a fraction of patients with B cell malignancies, but disease progression remains common. IL-15 promotes T cell proliferation and survival and may enhance CAR T cell efficacy. However, exploiting native IL-15 is challenging due to its unfavorable pharmacokinetics and tolerability. In contrast, NKTR-255 is a polymer-conjugated IL-15 that retains binding affinity to IL15Rα and exhibits reduced clearance, providing sustained pharmacodynamic responses.
Aims
We investigated the effects of NKTR-255 on human CD19 CAR T cells both in vitro and in an in vivo xenogeneic B cell lymphoma model.
Methods
T cells expressing a CD19/4-1BB/CD3ζ CAR were generated from healthy donors. For in vitro studies, CAR T cells were incubated with NKTR-255 (0-100 ng/mL) with and without CD19 antigen. STAT5 phosphorylation and CFSE dilution were assessed by flow cytometry. For in vivo studies, NSG mice received 5x105 Raji lymphoma cells IV on day (D)-7 and a subtherapeutic dose (0.8x106) of CAR T cells (1:1 CD4:CD8) on D0. NKTR-255 (0.03-0.3mg/kg IV) was administered weekly starting on D-1, 7, or 14. Tumor-free mice were rechallenged with Raji cells. Tumors were assessed by bioluminescence imaging.
Results
In vitro, NKTR-255 led to dose-dependent STAT5 phosphorylation and increased antigen-dependent proliferation of CD8 CAR T cells. In vivo, infusion of NKTR-255 starting at D-1, 7 or 14 increased peak CAR T cell numbers in blood. Raji cells were eliminated from marrow by D14 in mice receiving CAR T cells and NKTR-255 on D7, but not CAR T cells alone. There was superior NKTR-255 dose-dependent tumor control and survival in mice receiving CAR T cells with NKTR-255 compared to CAR T cells or NKTR-255 alone. The benefit of combination therapy with NKTR-255 and CART T cells was greater when NKTR-255 was started by D7. Residual CAR T cells in NKTR-255-treated mice rejected re-challenge of Raji tumor cells administered beyond 5 weeks after CAR T cell infusion.
Conclusion
NKTR-255 administration improves the antitumor efficacy and kinetics of CD19 CAR T cells, supporting advancement into clinical trials of combination therapy with NKTR-255 and approved CD19 CAR T cell products.
Session topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Res
Keyword(s): Immunotherapy, Lymphoma
{{ translation_no_result_event }}
{{ translation_no_result_session }}
{{ translation_no_result_conference }}
{{ translation_no_result_module }}
An error occurs, please refresh your page.
An error occurs, please refresh your page.
Upload content to be displayed on your "My Space" page.
Short message to be displayed on your "My Space" page. Maximum of 2000 characters.